Evidence map›Paper›PMID 26858990›Full record

ArticleTrends in cancer2016

Microfluidics: A new tool for modeling cancer-immune interactions.

Alexandra Boussommier-Calleja, Ran Li, Michelle B Chen, Siew Cheng Wong, Roger D Kamm

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. 3D Hybrid Bioprinting for Complex Multi-Tissue Engineering.bioRxiv : the preprint server for biology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Alexandra Boussommier-CallejaDepartment of Mechanical Engineering, MIT, Cambridge, MA, USA.
Ran LiDepartment of Biological Engineering, MIT, Cambridge, MA, USA.
Michelle B ChenDepartment of Mechanical Engineering, MIT, Cambridge, MA, USA.
Siew Cheng WongSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A-STAR), Biopolis, Singapore.
Roger D KammDepartment of Mechanical Engineering, MIT, Cambridge, MA, USA; Department of Biological Engineering, MIT, Cambridge, MA, USA.
IIT@MIT · USAgency for Science, Technology and Research · SG

Funding

Research Supplement - Quantitative analyses of tumor cell extravasationU01CA202177 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KAMM, ROGER D · 2015 to 2020
$4.2M
Microfluidic 3D Assays for Metastatic CancerR33CA174550 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KAMM, ROGER D · 2013 to 2015
$1.1M
NCI NIH HHS R33 CA174550NCI NIH HHS U01 CA202177
6 · The paper itself

Abstract

In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immune cells can intervene in the metastatic cascade, leading to the development of several

Indexed as

drug screeningimmunotherapymetastatic cancerMicrofluidics

Identifiers

PMID26858990
PMCPMC4743529
OpenAlexW2279226389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.